Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Glioblastoma 40Glioma 17Brain Neoplasms 14Astrocytoma 11Neuroblastoma 10Gliosarcoma 10Neoplasms 8Sarcoma, Ewing 7Rhabdomyosarcoma 6Recurrence 5Oligodendroglioma 5Sarcoma 4Medulloblastoma 4Neoplasm Metastasis 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Osteosarcoma 2Melanoma 2Lymphoma, Follicular 2Hepatoblastoma 2Central Nervous System Neoplasms 2Spinal Cord Neoplasms 1Somatostatinoma 1Rhabdoid Tumor 1Refractory Solid Tumors 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pheochromocytoma 1

Interventions

Temozolomide 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Temozolomide × 90 days × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡